A/Prof Piers Blombery
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
278 Scholarly works
8 Projects
HIGHLIGHTS
2024
Research grants (ARC, NHMRC, MRFF)
ADAPT (Achieving Durable Remission via Adaptive Pro-Survival Targeting in Acute Myeloid Leukaemia)
2023
Journal article
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
DOI: 10.1182/blood.20220160902022
Journal article
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
DOI: 10.1182/blood.20220160402022
Journal article
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
DOI: 10.1182/bloodadvances.20220083252022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752022
Research grants (ARC, NHMRC, MRFF)
Understanding and Averting Blood Cancer Resistance to Therapy
2021
Research grants (ARC, NHMRC, MRFF)
Diagnosis, Discovery and Novel Phenotype Characterisation Using Multimodal Genomics in Patients With Inherited Bone Marrow Failure and Related Disorders
RECENT SCHOLARLY WORKS
2026
Journal article
Activating somatic EPOR mutation in primary erythrocytosis
DOI: 10.1016/j.pathol.2026.04.0052026
Journal article
MAP3K14 (NIK) synonymous variants drive altered splicing to activate NF-κB in mature B-cell malignancies.
DOI: 10.1182/blood.20260342282026
Journal article
Novel chimeric PD-L1::PD-L2 fusion and immune evasion in lymphoma
DOI: 10.1038/s41698-026-01654-02026
Journal article
A quantitative definition of the clinical manifestations of GATA2 deficiency in adults.
DOI: 10.1182/blood.20260349422026
Journal article
Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia.
DOI: 10.1182/bloodadvances.20260207892026
Journal article
T-ALL: the origin story
DOI: 10.1182/blood.20250329442026
Journal article
MPL W515R hereditary thrombocytosis associated with a benign long-term clinical course
DOI: 10.1016/j.pathol.2025.12.0102026
Journal article
HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma
DOI: 10.1111/bjh.70478